mSphere · 2020 · 18 citations · 43 references
Life SciencesGeneticsMolecular GeneticsGenomicsMedical GeneticsPharmacogeneticsDrug Resistance GenomicsDrug-susceptible Tuberculosis TreatmentTuberculosis EpidemiologyDrug Resistance MutationsDrug Resistance TestingMolecular Drug ResistanceMultidrug Resistance EvolutionMultidrug-resistant Tuberculosis TreatmentSingle-nucleotide Polymorphism AnalysisSingle-nucleotide Polymorphism VariationTuberculosis Drug Resistance
Few studies have focused on the reasons for the low cure rate of multidrug-resistant tuberculosis in China and within-host evolution during treatment, which is of great significance for improving clinical treatment regimens. Acquired resistance events were common during the ineffective treatment, among which resistance to amikacin and high-level moxifloxacin were the most common. The main reason for the treatment failure of MDR-TB patients was insufficient effective drugs, which may lead to higher levels of drug resistance in MDR-TB strains. Therefore, the study emphasizes the importance of DST in the development of second-line treatment regimen when there is a risk of MDR. By performing whole-genome sequencing of serial strains from patients with treatment failure, we found that WGS can detect low-frequency resistance mutations and heterogeneous resistance with high sensitivity. It is thus recommended to conduct drug susceptibility tests at the beginning of treatment and repeat the DST when the sputum bacteria remain positive.
43
Global tuberculosis report (2014)
L.A. Gabbasova, E.R. Experts Who · 2014 · 13.2K citations
B. Jesse Shapiro, Răzvan Sultana, Alistair Calver et al. · Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) · 2013 · 467 citations